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Abstract
Background
Complex antithrombotic regimens are recommended for patients with atrial fibrillation (AF)
undergoing drug-eluting stent (DES) implantation but carry high bleeding risk.
Hypothesis
We aimed to evaluate whether left atrial appendage occlusion (LAAO) with dual antiplatelet
therapy (DAPT) improve clinical outcomes when compared with multiple antithrombotic
therapy (MAT) in patients with AF undergoing DES implantation.
Methods
Among 475 AF patients who underwent DES, 41 patients treated by LAAO with DAPT and
434 patients on MAT were compared. MAT was defined as any combination of warfarin-
based antithrombotic therapy. Among the MAT group, 34.8% were on triple antithrombotic
therapy. The primary endpoint was a net adverse clinical event (NACE), a composite of
cerebrovascular accident (CVA) and major bleeding. Secondary endpoints were CVA,
major bleeding, major adverse cardiac and cerebral event (MACCE), MI, cardiovascular
death, and all-cause death. Additional analysis between the new oral anticoagulant
(NOAC)-based antithrombotic therapy group (n = 45) and the LAAO group was performed
for the same endpoints. To adjust the confounding factors, inverse probability of treatment
weighting (IPTW) was applied during the endpoint analysis.
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Results
The LAAO group showed higher incidences of diabetes mellitus, prior CVA, higher
CHA2DS2-VASc score (4.56±1.55 vs. 2.96±1.60; P<0.0001), and higher HAS-BLED score
(3.24±1.20 vs. 2.13±0.75; P<0.0001). NACE occurred less frequently in the LAAO group
than the MAT group at 24 months (9.4% vs. 15.3%; hazard ratio 0.274; 95% confidence
interval 0.136 – 0.553; P = 0.0003), mainly driven by the reduction in major bleeding (2.4%
vs. 9.3%; hazard ratio 0.119; 95% confidence interval 0.032 – 0.438; P = 0.001). The LAAO
group with greater thrombotic and hemorrhagic risks showed comparable primary/second-
ary outcomes with the NOAC-based anti-thrombotic therapy group.
Conclusions
Among patients with AF who underwent DES implantation, the LAAO group had better net
clinical outcomes for preventing CVA and major bleeding than the MAT group. Further
large-scale trials including comparisons with NOACs are warranted.
Introduction
The number of patients with simultaneous atrial fibrillation (AF) and coronary artery disease
who require both antiplatelet and anticoagulation therapy is increasing in the aging society [1–
3]. According to the previous report, up to 15% of patients with AF previously suffered myocar-
dial infarction (MI) or ischemic heart disease [4]. In addition, 6-8% of patients undergoing per-
cutaneous coronary intervention (PCI) had an indication for oral anticoagulation (OAC) [5].
Current guidelines recommend complex regimens including triple antithrombotic therapy
(TAT) for patients undergoing PCI with AF [6, 7]. But the harms of TAT treatment, which
may occur bleeding, are thought to outweigh prevention of thromboembolism [5]. In a Danish
registry, major bleeding events occur primarily during the early period of medication, mostly
within 3 months from the onset of TAT [2, 4]. In the WOEST trial, which detected a high inci-
dence of bleeding in patients treated with TAT, most bleeding events were also concentrated
during the 2 months after randomization [8].
In patients who require both OAC and antiplatelet therapy, left atrial appendage occlusion
(LAAO) may have the potential benefit of requiring only antiplatelet agents without OAC.
However, studies comparing LAAO combined with dual antiplatelet therapy (DAPT) versus
conventional antithrombotic therapy in this setting are insufficient.
In the present study, we sought to compare the clinical outcomes of LAAO with DAPT ver-




The patient selection flow chart is shown in Fig 1. We identified 434 consecutive non-valvular
AF patients who underwent DES implantation in the PCI registry of Korea University Anam
Hospital and Sejong General Hospital from June 2003 to February 2014 and defined these
patients as the MAT group. This group of patients was treated with warfarin-based antithrom-
botic therapy. We also identified 41 patients who underwent DES implantation among 155
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consecutive patients in a Korean multicenter LAAO registry including 5 hospitals (Korea Uni-
versity Anam Hospital, Sejong General Hospital, Yonsei University Severance Hospital,
Gachon University Gil Hospital, and Ulsan University Hospital) from October 2010 to August
2016 as the LAAO group. We additionally identified 45 AF patients who underwent PCI and
treated with new oral anticoagulant (NOAC)-based antithrombotic therapy (NAT) from Octo-
ber 2013 to July 2020 as the NAT group for further comparison with the LAAO group. The
study protocol was approved by the Institutional Review Board of Korea University Anam
Hospital (2017AN0289). The informed consent was waived.
Definitions and endpoints
MAT was defined as any combination of warfarin-based anticoagulation or antiplatelet ther-
apy at discharge after the DES implantation. TAT was a subgroup of MAT defined as a combi-
nation of warfarin and DAPT. Time in therapeutic range (TTR) was defined as the proportion
of the time that international normalized ratio value remained between 2.0 and 3.0 according
to the Rosendaal method [9]. NAT was defined as any combination of NOAC-based anticoa-
gulation or antiplatelet therapy at discharge after the DES implantation.
The primary endpoint was a net adverse clinical event (NACE), a composite of cerebrovas-
cular accident (CVA) and major bleeding. CVA was defined as an ischemic cerebrovascular
event including both transient ischemic attack and ischemic cerebral infarction. Major bleed-
ing event was defined as a moderate or severe bleeding according to Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria
(GUSTO) [10]. In addition to GUSTO moderate or severe bleeding analysis, additional
Fig 1. Flowchart of patient selection.
https://doi.org/10.1371/journal.pone.0244723.g001
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analysis was conducted for events corresponding to Bleeding Academic Research Consortium
(BARC) type 3 or 5 bleeding [11].
Secondary endpoints were CVA, major bleeding, major adverse cardiac and cerebral event
(MACCE), MI, cardiovascular death, and all-cause death. All endpoints were further analyzed
in the comparison between the LAAO group and the TAT subgroup, and the comparison
between the LAAO group and the NAT group. MACCE was defined as a quadruple composite
of all-cause death, non-fatal MI, repeat revascularization, and CVA.
All endpoints were analyzed over a 24-month follow-up period. CVA were adjudicated by
neurologists. All other outcomes were adjudicated by the attending physicians.
Medical treatment and procedure protocol
The MAT group and the NAT group were composed of various subgroups. Selection of treat-
ment regimen was left to the discretion of the attending physician. Duration of regimen, TTR,
and de-escalation strategy were specified.
LAAO was indicated when patients had non-valvular AF with CHA2DS2-VASc�2 and
simultaneously had high risk of bleeding according to HAS-BLED score�3 or the following
contraindications of anticoagulation: 1) major bleeding event that occurred during anticoagula-
tion or 2) CVA during anticoagulation. The appendage dimension and anatomy were measured
using either computed tomography images or transesophageal echocardiography and fluoros-
copy. Device type was chosen according to the appendage morphology. Device size was 10-20%
larger than the diameter of the orifice to minimize post-procedural leakage. Implant success
was defined as confirmation of the device-specified release criteria and successful device release.
Peri-device leakage was defined as a residual leak>5mm observed by echocardiography.
Statistics
Continuous variables were expressed as mean ± standard deviation. Categorical variables were
expressed as frequency (percentage). Differences between the groups were analyzed using Stu-
dent’s t-test for continuous variables and Pearson’s χ2-test or Fisher’s exact test for categorical
variables. To adjust the confounding factors, inverse probability of treatment weighting (IPTW)
was applied during the endpoint analysis. Multilevel propensity score was calculated as the
probability of receiving LAAO based on the following variables: age, sex, smoking, dyslipidemia,
hypertension, diabetes mellitus, congestive heart failure, previous history of CVA, ejection frac-
tion, type of AF, lesion number of the coronary artery disease, and number and diameter of
implanted stents. Additional comparisons of the study endpoints between the LAAO group and
the TAT subgroup, and between the LAAO group and the NAT group were performed after the
independent IPTW adjustment using the same covariates mentioned above. We analyzed the
cumulative incidence rate from the index procedure time to the time of the first clinical out-
come of interest, estimated using the Kaplan–Meier method with log-rank test. We used the
Cox multivariate model incorporating covariates with P-value< 0.1 after IPTW adjustment to
examine the hazard ratio (HR) and 95% confidence interval (CI) of each endpoint. All tests
were two-tailed, with P-value<0.05 was considered significant. Statistical analysis was carried
out using the R statistical computing environment ver. 3.3.2 (R Development Core Team).
Results
Baseline characteristics
Baseline characteristics are shown in Table 1. Compared to the MAT group (n = 434), the
LAAO group (n = 41) was more likely to have diabetes mellitus, previous CVA, higher
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mean CHA2DS2-VASc score (4.56±1.55 vs. 2.96±1.60; P<0.0001), and higher mean
HAS-BLED score (3.24±1.20 vs. 2.13±0.75; P<0.0001). Follow-up duration was shorter in
the LAAO group. Most patients were treated with clopidogrel among P2Y12 inhibitors
(80.5% in the LAAO group, 96.8% in the MAT group). Although the clinical presentation of
Table 1. Baseline characteristics of the study population.
Total (n = 475) LAAO (n = 41) MAT (n = 434) P-value
Age (years) 68.0±9.2 69.6±8.3 67.9±9.2 0.2529
Age>65 329 (69.3) 28 (68.3) 301 (69.4) 0.8880
Age>75 100 (21.1) 11 (26.8) 89 (20.5) 0.3425
Male 318 (67.0) 32 (78.1) 286 (65.9) 0.1139
Follow-up period (days) 1255.2±906.1 590.5±420.3 1318.0±914.7 <0.0001
Smoking 0.0014
Never 292 (61.5) 36 (87.8) 256 (59.0)
Ex-smoker 112 (23.6) 3 (7.3) 109 (25.1)
Current smoker 71 (15.0) 2 (4.9) 69 (15.9)
HTN 358 (75.4) 29 (70.7) 329 (75.8) 0.4710
DM 149 (31.4) 20 (48.8) 129 (29.7) 0.0119
CHF 137 (28.8) 15 (36.6) 122 (28.1) 0.2522
Dyslipidemia 223 (47.0) 24 (58.5) 199 (45.9) 0.1198
Previous CVA 81 (17.1) 18 (43.9) 63 (14.5) <0.0001
CHADS2 score 1.91±1.22 2.71±1.27 1.83±1.19 <0.0001
CHA2DS2-VASc score 3.10±1.66 4.56±1.55 2.96±1.60 <0.0001
CHA2DS2-VASc�2 391 (82.3%) 41 (100.0) 350 (80.6) <0.0001
HAS-BLED score 2.23±0.85 3.24±1.20 2.13±0.75 <0.0001
EF (%) 52.13±13.26 54.35±11.01 51.92±13.45 0.2621
EF<40% 96 (20.2) 5 (12.2) 91 (21.0) 0.1812
Lesion number 2.11±1.06 2.00±0.86 2.12±1.06 0.6336
Stent number 1.54±0.81 1.28±0.51 1.57±0.83 0.0018
Diameter (mm) 2.97±0.43 3.14±0.50 2.92±0.42 0.0093
Length (mm) 34.79±22.27 22.00±7.78 35.97±22.79 <0.0001
AF type 0.6112
Paroxysmal 132 (27.8) 10 (24.4) 122 (28.1)
Persistent or permanent 343 (72.2) 31 (75.6) 312 (71.9)
Clinical presentation at index PCI 0.004
AMI 104 (21.9) 4 (9.8) 100 (23.0)
Unstable angina 237 (49.9) 15 (36.6) 222 (51.2)
Stable angina 110 (23.2) 11 (26.8) 99 (22.8)
ICMP 15 (3.2) 7 (17.1) 8 (1.8)
Silent myocardial ischemia 9 (1.9) 4 (9.8) 5 (1.2)
P2Y12 inhibitors 0.183
Clopidogrel 453 (95.4) 33 (80.5) 420 (96.8)
Ticagrelor 11 (2.3) 4 (9.8) 7 (1.6)
Prasugrel 4 (0.8) 4 (9.8) -
Miscellaneous 7 (1.5) - 7 (1.6)
Values are mean ± SD or n (%). AF = atrial fibrillation; AMI = acute myocardial infarction; CHD = coronary heart disease; CHF = congestive heart failure;
CVA = cerebrovascular accidents; DM = diabetes mellitus; EF = ejection fraction; HTN = hypertension; ICMP = ischemic cardiomyopathy; LAAO = left atrial
appendage occlusion; MAT = multiple antithrombotic therapy; PCI = percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0244723.t001
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acute coronary syndrome at index PCI was more frequent in the MAT group (46.4% in the
LAAO group, 74.2% in the MAT group), the use of potent P2Y12 inhibitors such as ticagre-
lor and prasugrel was rarer in the MAT group. IPTW-adjusted baseline characteristics are
shown in S1 Table in S1 File. Among the MAT group patients, 60.4% were treated with only
DAPT without anticoagulation at discharge, followed by TAT (34.8%) (Table 2). In the TAT
subgroup, mean TTR was low at 25.4%, and mean TAT duration was longer than 1 year.
TAT regimens were mostly de-escalated to DAPT or double antithrombotic therapy. Base-
line characteristics comparison between the LAAO group and the NAT group are shown in
S2 Table in S1 File. The NAT group were older (69.6±8.3 vs. 73.9±9.7; P = 0.021) and had
fewer incidence of chronic heart failure, dyslipidemia, and prior history of CVA. CHADS2
score, CHA2DS2-VASc score (4.56±1.55 vs. 3.24±1.43; P<0.001), and HAS-BLED score
(3.24±1.20 vs. 2.20±0.87; P<0.001) was significantly lower in the NAT group. Among the
NAT group, most of patients (80.0%) were prescribed with TAT, and the mean duration of
TAT was about 4 months (S3 Table in S1 File).
Procedure-related outcomes
Procedural characteristics of the LAAO group are summarized in Table 3. Two types of
devices, Amplatzer™ cardiac plug or Watchman™, were equally frequently used. The device suc-
cess rate was 92.7%. Among 3 cases of LAAO failure, 2 were due to size-mismatch, and 1 failed
due to appendage perforation. The complication rate of the procedure was 9.8%. No proce-
dure-related deaths occurred. One case of perforation during wiring into the appendage
resulted in conversion to surgery.
Clinical outcomes
IPTW-adjusted clinical outcomes between the LAAO group and the MAT group are sum-
marized in Table 4. The primary endpoint, composite of CVA and major bleeding,
occurred significantly less often in the LAAO group (9.4% vs. 15.3%; HR 0.274; 95% CI
0.136 – 0.553; P = 0.0003, Fig 2). Similar result was shown in the analysis for the composite
endpoint of CVA and BARC type 3 or 5 bleeding (4.9% vs. 14.1%; HR 0.191; 95% CI
0.037 – 0.992; P = 0.049, Fig 3). A beneficial but not significant trend was observed in the
LAAO group regarding the CVA rate. Major bleeding events (2.4% vs. 9.3%; HR 0.119;
95% CI 0.032 – 0.438; P = 0.001), BARC type 3 or 5 bleeding events (2.4% vs. 9.4%; HR
0.082; 95% CI 0.010 – 0.657; P = 0.019), and MACCE (18.1% vs. 20.4%; HR 0.383; 95% CI
Table 2. Composition of the multiple antithrombotic therapy group.




Time in therapeutic range (%) 25.36±23.49
De-escalation after TAT
DAPT 43 (28.5)
Double antithrombotic therapy 41 (27.2)
Miscellaneous 3 (2.0)
Not available 64 (42.4)
Miscellaneous (Double or quadruple antithrombotic therapy) 21 (4.8)
Values are mean ± SD or n (%). DAPT = dual antiplatelet therapy; TAT = triple antithrombotic therapy.
https://doi.org/10.1371/journal.pone.0244723.t002
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0.218 – 0.673; P = 0.001) were also less frequently shown in the LAAO group. The two car-
diovascular deaths in the LAAO group occurred more than 1 year after the index proce-
dure and were due to MI and sudden cardiac death. These deaths contributed to the
significant differences observed between the two groups (11.9% vs. 2.2%; HR 3.813; 95% CI
1.297 – 11.209; P = 0.015). There were no significant differences between the LAAO group
and the MAT group regarding all-cause death. Similar results were observed in comparison
between the LAAO group and the TAT subgroup (S4 Table in S1 File). The incidence of
NACE was lower in the LAAO group than the TAT subgroup (9.4% vs. 19.0%; HR 0.34;
95% CI 0.146 – 0.795; P = 0.013, S1 Fig). However, there was no difference in MACCE
between the LAAO group and the TAT subgroup. The comparison between the non-TAT
subgroup and the LAAO group also showed a similar trend to the MAT group and the
LAAO group (S2 Fig and S5 Table in S1 File). The comparison between the NAT group
and the LAAO group regarding primary endpoint and secondary endpoints showed no sta-
tistical differences (S3 Fig and S6 Table in S1 File).
Table 3. Procedural characteristics in the left atrial appendage occlusion group.
Variables n = 41
LA diameter (mm) 48.44±8.44
LA volume index (ml/m2) 52.18±24.83
LAA type
Chicken wing 7 (17.1)
Wind sock 8 (19.5)
Cauliflower 3 (7.3)
Cactus 4 (9.8)
Not available 19 (46.3)











ACP or ACP II 20 (48.8)
Watchman™ 21 (51.2)
Device size (mm) 25.77±2.83
Successful implantation 38 (92.7)
Peri-device leakage 0 (0)
Complications 4 (9.8)
Pericardial effusion 1 (2.4)
Cardiac tamponade 1 (2.4)
LAA perforation 1 (2.4)
Vascular access site bleeding 1 (2.4)
Values are mean ± SD or n (%). ACP = Amplatzer™ cardiac plug; LA = left atrium; LAA = left atrial appendage;
LAAO = left atrial appendage occlusion; SEC = spontaneous echo contrast.
https://doi.org/10.1371/journal.pone.0244723.t003
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Relative risk reductions of CVA and major bleeding
During a 66.3-person-year follow-up, the actual annual rate of CVA and major bleeding was
1.54 events per 100 patient-years in the LAAO group (Fig 4). The expected annual rates of rela-
tive risk reduction (RRR) calculated using CHA2DS2-VASc and HAS-BLED scores were
82.6% for CVA and 76.9% for major bleeding, respectively. In the MAT group, RRR was
Table 4. Inverse probability of treatment weighting -adjusted clinical outcomes at 24 months of follow-up.
Variables LAAO (n = 41) MAT (n = 434) Hazard ratio (95% Confidence interval) P-value
CVA or major bleeding 2 (9.4%) 59 (15.3%) 0.274 (0.136 – 0.553) 0.0003
CVA 1 (7.1%) 26 (6.9%) 0.493 (0.208 – 1.17) 0.109
Major bleeding 1 (2.4%) 36 (9.3%) 0.119 (0.032 – 0.438) 0.001
CVA or BARC type 3/5 bleeding 2 (4.9%) 61 (14.1%) 0.191 (0.037 – 0.992) 0.049
BARC type 3/5 bleeding 1 (2.4%) 41 (9.4%) 0.082 (0.010 – 0.657) 0.019
Myocardial infarction 1 (5.6%) 11 (2.9%) 0.251 (0.047 – 1.345) 0.107
MACCE 3 (18.1%) 79 (20.4%) 0.383 (0.218 – 0.673) 0.001
Cardiovascular death 2 (11.9%) 9 (2.2%) 3.813 (1.297 – 11.209) 0.015
All-cause death 2 (11.9%) 23 (5.8%) 0.915 (0.401 – 2.088) 0.833
Data shown are number of patients (%). Event rates are Kaplan-Meier estimates. Adjusted variables for Cox analysis were smoking, diabetes mellitus, ejection fraction,
stent number, and stent length. BARC = Bleeding Academic Research Consortium; CVA = cerebrovascular accidents; DAPT = dual antiplatelet therapy; LAAO = left
atrial appendage occlusion; MACCE = major adverse cardiac and cerebral event; MAT = multiple antithrombotic therapy.
https://doi.org/10.1371/journal.pone.0244723.t004
Fig 2. Kaplan Meier curve: Freedom from clinical outcomes between the left atrial appendage occlusion group and the multiple antithrombotic therapy
group during 24 months of follow-up. A: Rates of composite of cerebrovascular accidents (CVA) or major bleeding; B: Rates of CVA; C: Rates of major
bleeding; D: Rates of major adverse cardiac and cerebral events (MACCE); E: Rates of cardiovascular death; F: Rates of all-cause death.
https://doi.org/10.1371/journal.pone.0244723.g002
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Fig 3. Kaplan Meier curve: Freedom from clinical outcomes using Bleeding Academic Research Consortium (BARC) definition for bleeding between the
left atrial appendage occlusion group and the multiple antithrombotic therapy group during 24 months of follow-up. A: Rates of composite of
cerebrovascular accidents (CVA) or BARC type 3/5 bleeding; B: Rates of BARC type 3/5 bleeding.
https://doi.org/10.1371/journal.pone.0244723.g003
Fig 4. Expected and observed CVA and bleeding events according to study group. Expected rates of CVA (A) and
bleeding events (B) based on CHA2DS2-VASc and HAS-BLED scores were compared with observed event rates.
https://doi.org/10.1371/journal.pone.0244723.g004
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44.8% and 17.0%, respectively. In the TAT subgroup, RRR of CVA was 65.1%, but major
bleeding was 23.5% higher than expected. In the non-TAT subgroup, RRR of CVA was 36.1%
and RRR of major bleeding was 39.2% (S4 Fig).
Subgroup analysis
In subgroup analyses of the primary endpoint at 24-months involving comparisons between
the LAAO group and the MAT group, the LAAO group had better outcomes in terms of pre-
venting CVA and major bleeding across the most subgroups (Fig 5). However, patients youn-
ger than 65 years, female patients, patients with diabetes mellitus, and patients without acute
coronary syndrome experienced neutral effects associated with LAAO.
Discussion
Study findings
This study demonstrated that LAAO with DAPT resulted in net clinical benefit in terms of
preventing both CVA and major bleeding compared with MAT in patients with AF undergo-
ing DES implantation. This result was mainly driven by the reduction of major bleeding,
which suggests that LAAO may simultaneously reduce bleeding risk and prevent CVA, given
that the bleeding risk associated with OAC could be avoided by LAAO. The clinical benefit of
the LAAO group was consistently shown in the analysis using the BARC bleeding criteria
instead of the GUSTO bleeding criteria. Major bleeding events were most frequent (13.24% at
24 months) in the TAT subgroup. We also obtained an acceptable success rate of 92.7% and
Fig 5. Subgroup analysis plot of the primary endpoint between the left atrial appendage occlusion group and the
multiple antithrombotic therapy group.
https://doi.org/10.1371/journal.pone.0244723.g005
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complication rate of 9.8% for the LAAO procedure, rates comparable with those reported in
recent global studies [12, 13]. TAT was substantially under-prescribed in the MAT group, and
the mean TTR value was low. These findings are in line with those of previous studies, which
demonstrated underuse of TAT and low TTR rates of warfarin [14, 15]. This study also found
poor compliance with adequate de-escalation of the regimen, as in the previous study [16].
The LAAO group with greater thrombotic and hemorrhagic risks showed comparable clinical
outcomes with the NAT group in the present study. However, since the number of subjects
was quite limited in our study, the results of the present study should be reconfirmed in large-
scale studies.
Pitfalls of conventional antithrombotic therapy
The latest European guidelines recommend to treat AF patients who are in need of OAC with
short-term TAT (1 week to 1 month) after PCI according to ischemic, thrombotic, and bleed-
ing risk and with sequential double therapy with OAC and aspirin or clopidogrel for a few
months, followed by lifelong OAC monotherapy [6, 7]. However, these regimens include
diverse de-escalating strategies and are very complex for both physicians and patients. In addi-
tion, these regimens may substantially increase bleeding risk, especially during the early TAT
period [2, 8]. Recent studies have demonstrated that both average daily bleeding rates and
average daily ischemic rates are highest during the first month immediately after PCI, followed
by a gentle downward curve [17, 18]. These high bleeding rate and ischemic rate in the first
month after the PCI is estimated to be even higher in AF patients undergoing PCI. Therefore,
during the early period after PCI, where both average daily bleeding rates and average daily
ischemic rates are high, LAAO, which may prevent both bleeding and thromboembolism, is
expected to be useful in this particular patient population.
Recent trials have demonstrated the safety of new antithrombotic regimens including
NOAC, their efficacy has not been fully evaluated and these trials excluded patients with
advanced chronic kidney disease [19–21]. Unfortunately, with relatively small study subjects,
patients with advanced chronic kidney disease who are not eligible for NOAC treatment
(chronic kidney disease> = stage 4 15/475, 3.2% of total study population) were very rare,
thereby conducting subgroup analysis was not applicable in our study. Future studies should
be discussed further focusing on this special situation.
In addition, vitamin K antagonist has been used for preventing thromboembolic events in
patients with non-valvular AF patients for over 60 years [22]. Thus, it is expected that a signifi-
cant number of non-valvular AF patients are still being treated with warfarin. Also, with the
aging of society, the number of patients who cannot be treated with NOAC, such as patients
with advanced chronic kidney disease is increasing significantly. We believe that the results of
this study can be a meaningful reference for patients who need to maintain warfarin, not
NOAC, that is, patients with valvular AF or mechanical valve replacement.
Combinations of LAAO with DAPT
It is well known that LAAO shows a CVA prevention effect equivalent to that of anticoagula-
tion but is associated with several procedure-related complications [23–25]. Therefore, the
benefits and risks of LAAO for AF patients undergoing DES implantation should be addressed
before widespread usage. Although complication rates ranged from 8% to 12% during the
early period after LAAO introduction, they have rapidly decreased to 4% [12, 26]. Therefore, if
LAAO is performed by experienced physicians, it is thought to be safe [12, 27]. In addition,
LAAO with DAPT strategy may have additional potential strengths when used to treat patients
with AF undergoing DES implantation.
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First, patients may be free of OAC after LAAO procedure, thereby avoiding the high risk of
bleeding associated with the early TAT period [28]. Furthermore, serial monitoring of TTR of
warfarin is not necessary. New potent P2Y12 inhibitors such as ticagrelor or prasugrel are also
available for use in this novel treatment strategy [29].
Second, antithrombotic regimens prescribed after PCI for patients with AF could be simpli-
fied to DAPT only. Treatment with LAAO is therefore expected to improve compliance.
Third, this treatment strategy will be of great value for treating patients with advanced
chronic kidney disease who are at high bleeding risk and in whom the use of NOAC is
contraindicated.
The Munich consensus suggested that LAAO is a potential indication for PCI in patients
with AF [30], and the results of the present study support that suggestion. Based on this back-
ground, two prospective studies comparing LAAO with DAPT and antithrombotic therapy
including NOACs are currently ongoing (NCT02492230, NCT02606552).
Limitations
Our study has several limitations. First, this study has all the inherent limitations of small ret-
rospective study. Sample calculation was not possible because this study was a retrospective
study dealing with a topic that had not been studied previously. Also, different cohorts of
patients were derived from different time periods. Thus, the LAAO group had higher cerebro-
vascular risk, but had shorter follow-up for events to accrue. To compensate different follow-
up period between the two groups, we analyzed and provided observation data up to 2 years.
Second, the MAT group was highly disparate, and the duration of TAT was longer than sug-
gested by the current guidelines. The diversity of antithrombotic regimens and variable dura-
tion of antithrombotic therapy, and low TTR might significantly affect clinical outcomes in
present study. However, our findings might better reflect real-world practice and underscore
the difficulty of following treatment guidelines. Third, in comparison between the NAT group
and the LAAO group, the number of subjects in both groups was relatively small compared to
the number of clinical events. Therefore, it should not be generalized that there is no difference
in clinical outcomes between the NOAC-based antithrombotic strategy and the LAAO with
DAPT strategy and should be reconfirmed in larger scale studies. Fourth, LAAO device failure
was not included in study endpoints, since the purpose of this study was to prove that the
bleeding event as well as the ischemic event can be reduced by performing the LAAO proce-
dure. Fifth, data on coronary artery disease complexity such as SYNTAX score were not col-
lected in this study. Sixth, only Koreans were included in this study. Therefore, it should be
decided carefully to apply the results of this study to other ethnicities.
Conclusions
LAAO with DAPT results in better net clinical outcomes in terms of preventing CVA and
major bleeding than the MAT in patients with AF undergoing DES implantation. Further
large-scale trials including comparisons with NOACs are warranted.
Supporting information
S1 Fig. Kaplan Meier curve. Freedom from clinical outcomes between the left atrial append-
age occlusion group and the triple antithrombotic therapy subgroup during 24 months of fol-
low-up. A: Rates of composite of cerebrovascular accidents (CVA) and major bleeding; B:
Rates of CVA; C: Rates of major bleeding; D: Rates of major adverse cardiac and cerebral
events (MACCE); E: Rates of cardiovascular death; F: Rates of all-cause death.
(TIF)
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S2 Fig. Kaplan Meier curve. Freedom from clinical outcomes between the left atrial append-
age occlusion group and the non-triple antithrombotic therapy subgroup during 24 months of
follow-up. A: Rates of composite of cerebrovascular accidents (CVA) and major bleeding; B:
Rates of CVA; C: Rates of major bleeding; D: Rates of major adverse cardiac and cerebral
events (MACCE); E: Rates of cardiovascular death; F: Rates of all-cause death.
(TIF)
S3 Fig. Kaplan Meier curve. Freedom from clinical outcomes between the left atrial append-
age occlusion group and the new oral anticoagulant (NOAC)-based antithrombotic therapy
group during 24 months of follow-up. A: Rates of composite of cerebrovascular accidents
(CVA) and major bleeding; B: Rates of CVA; C: Rates of major bleeding; D: Rates of major
adverse cardiac and cerebral events (MACCE); E: Rates of cardiovascular death; F: Rates of all-
cause death.
(TIF)
S4 Fig. Expected and observed cerebrovascular accidents (CVA) and bleeding events
between the left atrial appendage occlusion group and the non-triple antithrombotic ther-
apy subgroup. Expected rates of CVA (A) and bleeding events (B) based on CHA2DS2-VASc
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